Wall Street Analysts See a 27.66% Upside in Amneal ( AMRX ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Boston Scientific ( BSX ) This Year?
Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Here's Why Momentum in Amneal ( AMRX ) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Amneal ( AMRX ) Q2 EPS Jumps 56%
Amneal Pharmaceuticals ( NASDAQ:AMRX ) , a developer and manufacturer of specialty and generic pharmaceuticals, released its second quarter earnings on August 5, 2025. The company reported stronger-than-expected profitability, as non-GAAP EPS of $0.25 exceeded analyst estimates, with adjusted ...
Knight Therapeutics Announces Regulatory Submission of CREXONT® ( Carbidopa and Levodopa ) Extended-Release Capsules in Mexico
MONTREAL, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization ...
Amneal Pharmaceuticals ( AMRX ) Q2 Earnings Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amneal Reports Second Quarter 2025 Financial Results
‒ Q2 2025 Net Revenue of $725 million. GAAP Net Income of $22 million. Diluted Income per Share of $0.07 ‒‒ Adjusted EBITDA of $184 million. Adjusted Diluted EPS of $0.25 ‒‒ Raising 2025 Full Year Guidance ‒‒ Full Debt Refinancing Reduces Interest Cost and Extends Maturities to ...
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Amneal ( AMRX ) is an Incredible Growth Stock: 3 Reasons Why
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal Pharmaceuticals ( AMRX ) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Amneal ( AMRX ) Could Surge 43.82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Amneal Pharmaceuticals ( AMRX ) Outperforming Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., July 21, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" ) AMRX announced that its subsidiary, Amneal Pharmaceuticals LLC ( the "Issuer" ) , is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans ( the "new term B ...
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
BRIDGEWATER, N.J., July 21, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" ) ( Nasdaq: AMRX ) announced that its subsidiary, Amneal Pharmaceuticals LLC ( the "Issuer" ) , is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans ( the "new ...
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
- Results Reflect Continued Financial Strength and ...
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® ( Carbidopa and Levodopa ) Extended-Release Capsules in Canada
MONTREAL, July 18, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that Knight's New Drug Submission ( NDS ) for CREXONT® has been accepted for review by Health Canada.
Indivior ( INDV ) Moves 5.7% Higher: Will This Strength Last?
Indivior (INDV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Has Amneal Pharmaceuticals ( AMRX ) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Amneal Pharmaceuticals ( AMRX ) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
BRIDGEWATER, N.J., June 12, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced the U.S. Food and Drug Administration ( FDA ) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®.
Catalyst Pharmaceuticals, Inc. ( CPRX ) Hits Fresh High: Is There Still Room to Run?
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Believe Amneal ( AMRX ) Could Rally 54.36%: Here's is How to Trade
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Reasons Growth Investors Will Love Amneal ( AMRX )
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Amneal Receives U.S. FDA Approval for Brekiya® ( dihydroergotamine mesylate ) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
BRIDGEWATER, N.J., May 15, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( Nasdaq: AMRX ) ( "Amneal" or the "Company" ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Brekiya® ( dihydroergotamine mesylate ) injection, the first and only dihydroergotamine ...
Does Amneal ( AMRX ) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is Why Growth Investors Should Buy Amneal ( AMRX ) Now
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock?
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Q1 adjusted EPS rose to $0.21 from $0.14, beating estimates; sales grew 5% to $695 million but missed the $715 million consensus. Net income hit $12 million vs. a $92 million loss last year; adjusted EBITDA rose 12% to $170 million on higher margins and expense leverage
Amneal Pharmaceuticals ( AMRX ) Q1 Earnings Beat Estimates
Amneal (AMRX) delivered earnings and revenue surprises of 40% and 2.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
Amneal Pharmaceuticals ( AMRX ) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Crexont improved sleep quality in PD patients with a PDSS-2 score difference of -2.35 vs. IR CD/LD. More Crexont patients woke up in an "On" state and fewer reported waking "Off" vs. IR CD/LD in diary analysis. With stocks plunging, steady income is key.
Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR
Wilmington, Delaware, Transparency Market Research Inc. -, March 07, 2025 ( GLOBE NEWSWIRE ) -- Rising awareness about women's reproductive health and increasing prevalence of hormonal disorders are driving the growth of the Polycystic Ovarian Syndrome Treatment Market.
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and adjusted EBITDA of $650M-$675M. Our government trade tracker caught Pelosi's 169% AI winner.
Amneal Pharmaceuticals ( AMRX ) Q4 Earnings Lag Estimates
Amneal (AMRX) delivered earnings and revenue surprises of -20% and 3.15%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Esperion Therapeutics ( ESPR ) Report Negative Earnings Next Week? What You Should Know
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street's Insights Into Key Metrics Ahead of Amneal ( AMRX ) Q4 Earnings
Evaluate the expected performance of Amneal (AMRX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Amneal ( AMRX ) Soars 6.0%: Is Further Upside Left in the Stock?
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Crexont prescriptions reached 964 per week by mid-February, capturing 15% of Rytary's volume and exceeding market expectations. JP Morgan upgraded Amneal to Overweight, raising its price target to $12, citing strong generics growth and expanding biosimilar adoption.
Amneal Pharmaceuticals ( AMRX ) Reports Next Week: Wall Street Expects Earnings Growth
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amneal ( AMRX ) Beat Estimates Again in Its Next Earnings Report?
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Acute Agitation and Aggression Treatment Market to Exceed USD 8.2 Billion by 2034, Driven by Advancements in Rapid-Acting Therapies - Latest Report by Transparency Market Research Inc.
Wilmington, Delaware, Transparency Market Research Inc. - , Feb. 06, 2025 ( GLOBE NEWSWIRE ) -- The global acute agitation and aggression treatment market was valued at approximately US$ 5.0 billion in 2023. It is projected to grow at a CAGR of 4.6% from 2024 to 2034, reaching around US$ 8.2 ...
Wall Street Analysts Predict a 27.12% Upside in Amneal ( AMRX ) : Here's What You Should Know
The consensus price target hints at a 27.1% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Sinusitis Treatment Market Set to Reach US$ 3.5 Bn by 2031, Driven by Rising Cases and Advanced Treatment Options | Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc. -, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- With the global burden of sinusitis on the rise, the Sinusitis Treatment Market ( Sinusitis-Behandlungsmarkt ) is undergoing significant transformation.
Corcept Therapeutics Incorporated ( CORT ) Hit a 52 Week High, Can the Run Continue?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Amneal Pharmaceuticals ( AMRX ) Stock Outpacing Its Medical Peers This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
